LoopLab Bio
Startup
www.looplab.bio/Vienna, AustriaAbout
LoopLab Bio is a Vienna-based biotechnology company developing a next-generation immunology platform for antigen-specific immune tolerance. The company focuses on enabling highly precise modulation of the immune system without broad immunosuppression.
LoopLab Bio’s proprietary Fc-Engager platform is designed to selectively reprogram pathogenic immune responses, with potential applications in autoimmune diseases, allergies, and the prevention of anti-drug antibodies. By targeting disease-relevant immune mechanisms with high specificity, the platform aims to deliver safer and more durable therapeutic outcomes.
The company is advancing multiple preclinical programs while completing lead candidate selection supported by robust in vivo and translational research. LoopLab Bio is backed by strong non-dilutive funding and international early-stage investment and is building strategic collaborations to accelerate development and future clinical translation.
Founded by an experienced team with deep expertise across immunology, biotechnology, and pharmaceutical development, LoopLab Bio is positioned as a next-generation player in targeted immunotherapy, with a modular and scalable technology platform designed for long-term impact.
Impact Area
Representatives
COO / Co - Founder
LoopLab Bio